Full Committee Hearing: “Developments in the Prescription Drug Market: Oversight”

Invited Witnesses

Dr. Janet Woodcock
Director, Center for Drug Evaluation and Research    
U.S. Food and Drug Administration    

Mr. Howard B. Schiller
Interim Chief Executive Officer    
Valeant Pharmaceuticals International, Inc.    

Mr. Martin Shkreli
Former Chief Executive Officer    
Turing Pharmaceuticals LLC    

Ms. Nancy Retzlaff
Chief Commercial Officer    
Turing Pharmaceuticals LLC    

Mr. Mark Merritt
President and Chief Executive Officer    
Pharmaceutical Care Management Association